Comments
Loading...

Genmab

GMABNASDAQ
Logo brought to you by Benzinga Data
$21.81
-0.04-0.18%
At close: -
$21.81
0.000.00%
After Hours: Dec 6, 4:00 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$50.00
Lowest Price Target1
$31.00
Consensus Price Target1
$40.56

Genmab (NASDAQ:GMAB) Stock, Analyst Ratings, Price Targets, Forecasts

Genmab AS has a consensus price target of $40.56 based on the ratings of 13 analysts. The high is $50 issued by HC Wainwright & Co. on October 16, 2024. The low is $31 issued by Morgan Stanley on September 11, 2024. The 3 most-recent analyst ratings were released by BMO Capital, HC Wainwright & Co., and HC Wainwright & Co. on November 8, 2024, October 16, 2024, and September 20, 2024, respectively. With an average price target of $49.33 between BMO Capital, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 126.20% upside for Genmab AS from these most-recent analyst ratings.

Analyst Trends and Forecast
5
1
Aug
4
2
Sep
1
Oct
1
Nov
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
2.1
Sell
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

BMO Capital
HC Wainwright & Co.
Morgan Stanley
Truist Securities
BTIG

1calculated from analyst ratings

Analyst Ratings for Genmab

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Genmab (GMAB) stock?

A

The latest price target for Genmab (NASDAQ:GMAB) was reported by BMO Capital on November 8, 2024. The analyst firm set a price target for $48.00 expecting GMAB to rise to within 12 months (a possible 120.08% upside). 33 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Genmab (GMAB)?

A

The latest analyst rating for Genmab (NASDAQ:GMAB) was provided by BMO Capital, and Genmab reiterated their outperform rating.

Q

When was the last upgrade for Genmab (GMAB)?

A

The last upgrade for Genmab AS happened on July 15, 2024 when RBC Capital raised their price target to N/A. RBC Capital previously had a sector perform for Genmab AS.

Q

When was the last downgrade for Genmab (GMAB)?

A

The last downgrade for Genmab AS happened on August 20, 2024 when JP Morgan changed their price target from N/A to N/A for Genmab AS.

Q

When is the next analyst rating going to be posted or updated for Genmab (GMAB)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Genmab, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Genmab was filed on November 8, 2024 so you should expect the next rating to be made available sometime around November 8, 2025.

Q

Is the Analyst Rating Genmab (GMAB) correct?

A

While ratings are subjective and will change, the latest Genmab (GMAB) rating was a reiterated with a price target of $46.00 to $48.00. The current price Genmab (GMAB) is trading at is $21.81, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch